Charles Fitzgerald Buys 27,600 Shares of Global Medical REIT (NYSE:XRN) Stock

Global Medical REIT Inc. (NYSE:XRN) Director Charles Fitzgerald bought 27,600 shares of Global Medical REIT stock in a transaction dated Monday, August 10th. The stock was purchased at an average cost of $35.94 per share, for a total transaction of $991,944.00. Following the completion of the acquisition, the director directly owned 124,893 shares of the company’s stock, valued at approximately $4,488,654.42. The trade was a 28.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Charles Fitzgerald also recently made the following trade(s):

• On Tuesday, August 11th, Charles Fitzgerald bought 14,000 shares of Global Medical REIT stock. The stock was purchased at an average price of $35.78 per share, for a total transaction of $500,920.00.

Global Medical REIT Price Performance

Shares of Global Medical REIT stock opened at $36.52 on Friday. The stock has a 50 day moving average of $36.59 and a 200 day moving average of $35.80. Global Medical REIT Inc. has a 12 month low of $29.05 and a 12 month high of $39.93. The firm has a market cap of $483.50 million, a PE ratio of 9.82 and a beta of 1.09. The company has a current ratio of 0.68, a quick ratio of 0.68 and a debt-to-equity ratio of 1.68.

Global Medical REIT (NYSE:XRN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $4.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $3.95. Global Medical REIT had a return on equity of 13.74% and a net margin of 36.82%.The business had revenue of $39.75 million for the quarter. On average, research analysts expect that Global Medical REIT Inc. will post 3.06 EPS for the current fiscal year.

Analysts Set New Price Targets

XRN has been the subject of a number of analyst reports. Compass Point reaffirmed a “neutral” rating and issued a $38.00 price target (down from $50.00) on shares of Global Medical REIT in a report on Thursday, May 7th. Zacks Research raised Global Medical REIT to a “hold” rating in a research note on Wednesday, July 22nd. Citizens Jmp upped their price objective on Global Medical REIT from $40.00 to $42.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 26th. Weiss Ratings lowered Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Raymond James Financial started coverage on Global Medical REIT in a report on Wednesday, June 17th. They issued a “market perform” rating for the company. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $40.25.

Institutional Investors Weigh In On Global Medical REIT

Several institutional investors have recently made changes to their positions in XRN. Caitong International Asset Management Co. Ltd grew its holdings in Global Medical REIT by 1,001.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 793 shares of the company’s stock valued at $27,000 after purchasing an additional 721 shares during the last quarter. Fifth Third Bancorp lifted its stake in Global Medical REIT by 35.3% in the fourth quarter. Fifth Third Bancorp now owns 1,417 shares of the company’s stock worth $48,000 after purchasing an additional 370 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Global Medical REIT by 70.3% in the second quarter. Tower Research Capital LLC TRC now owns 7,379 shares of the company’s stock worth $51,000 after purchasing an additional 3,046 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of Global Medical REIT during the second quarter valued at approximately $78,000. Finally, Virtus Advisers LLC boosted its position in shares of Global Medical REIT by 46.5% during the fourth quarter. Virtus Advisers LLC now owns 2,418 shares of the company’s stock valued at $82,000 after buying an additional 768 shares during the period. Institutional investors own 57.52% of the company’s stock.

Global Medical REIT News Summary

Here are the key news stories impacting Global Medical REIT this week:

• Positive Sentiment: Director Charles Fitzgerald purchased 14,000 shares for approximately $500,920 at an average price of $35.78, increasing his direct ownership by 11.21%. This followed his purchase of another 27,600 shares, worth about $991,944, on August 10. SEC insider purchase filing
• Positive Sentiment: CEO Mark Okey Decker Jr. bought 8,000 shares for $287,040 on August 10 and an additional 550 shares for $19,800 on August 11. The purchases increased his holdings by 13.38% and 0.81%, respectively, signaling management confidence in the company’s valuation and outlook. CEO insider buying report
• Positive Sentiment: Global Medical REIT reported quarterly earnings per share of $4.78, exceeding the $0.83 consensus estimate by $3.95, with revenue of $39.75 million. The company posted a 36.82% net margin and 13.74% return on equity, while analysts expect full-year EPS of $3.06.
• Positive Sentiment: Some analysts remain constructive: Citizens JMP raised its price target to $42 from $40 and maintained an outperform rating. The average analyst price target is $40.25, above the recent trading level.
• Neutral Sentiment: Institutional ownership remains substantial at 57.52%. Invesco increased its position, and several other investment firms recently initiated or expanded holdings, providing some support from professional investors.
• Negative Sentiment: Analyst sentiment is mixed, with an overall “Hold” rating. Compass Point cut its price target to $38 from $50, Wall Street Zen downgraded the stock to “Sell,” and Raymond James initiated coverage at “Market Perform.”
• Negative Sentiment: The REIT carries meaningful leverage, with a debt-to-equity ratio of 1.68 and current and quick ratios of 0.68, factors that could limit financial flexibility if interest rates or property-market conditions worsen.

Global Medical REIT Company Profile

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.